Achilles drops cell therapy program, braces for layoffs
WEB2 days ago · Achilles ended last year with 204 full-time employees plus 11 part-time staffers. A workforce reduction and other cost-cutting measures are in the works, but the details are still taking shape as ...
Achilles Therapeutics Announces Strategic Update
WEB3 days ago · Achilles Therapeutics Announces Strategic Update. Sep 19 2024. –Achilles to discontinue development of TIL-based cNeT therapy–. –Cash position of $95.1 million as of June 30, 2024–. –BofA Securities engaged to provide strategic financial advice–. LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- …
Achilles stock climbs on strategic focus (NASDAQ:ACHL)
WEB2 days ago · Achilles Therapeutics (NASDAQ: ACHL) ADRs added ~42% in the premarket on Thursday after the U.K.-based biotech announced plans to explore strategic alternatives and close its CHIRON and THETIS ...
Achilles Therapeutics to Lay Off Staff as Part of Review, …
WEB3 days ago · As of June 30, Achilles Therapeutics said it had $95.1 million in cash and cash equivalents. The company also said it has discontinued its TIL-based cNeT program and closed the phase 1/2a Chiron ...
Achilles Therapeutics Shares Are Trading Higher: What You
WEB3 days ago · Achilles Therapeutics is discontinuing its TIL-based cNeT program and closing its Phase I/IIa CHIRON and THETIS clinical trials The company's stock surged 31.7% in response to this announcement ...
Achilles Therapeutics plc (ACHL) Stock Price, Quote & News
WEBSep 10, 2024 · Get a real-time Achilles Therapeutics plc (ACHL) stock price quote with breaking news, financials, statistics, charts and more.
Achilles Therapeutics plc (ACHL) Stock Price, News, Quote
WEBFind the latest Achilles Therapeutics plc (ACHL) stock quote, history, news and other vital information to help you with your stock trading and investing.
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 ...
WEBApr 4, 2024 · Achilles is a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed...
Achilles Therapeutics Provides Interim Phase I/IIa Update on …
WEBLONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells (cNeT) from the CHIRON ...
Achilles Therapeutics Announces Publication of Nature Cancer …
WEBDec 18, 2023 · Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction. Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapies.
- Some results have been removed
Skip to content